TP53 and myelodysplastic syndrome: Additionally, the presence of TP53 mutations, an early initiating event in MDS/AML transformation in patients with SDS (Xia et al., 2018; Kennedy et al., 2021), suggests that a “dual-hit” mechanism drives clonal evolution, leading to MDS progression.